InvestorsHub Logo
Followers 10
Posts 1249
Boards Moderated 0
Alias Born 07/20/2020

Re: None

Wednesday, 06/07/2023 11:24:36 AM

Wednesday, June 07, 2023 11:24:36 AM

Post# of 53
$1.65 -Phase 3 results within days if positive this low floater could double or triple quickly

company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .

Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DERM News